Search results for "THROMBOSIS"

showing 10 items of 630 documents

Acute inferior myocardial infarction due to a large thrombus in the Left coronary sinus of valsalva.

2021

Background Masses in the ascending aorta are an uncommon source of coronary embolism: thrombi located on atherosclerotic aortic plaques are the most frequent cause. A floating thrombus, without evidence of ascending aortic pathology has rarely been reported Method We report a case of an unusual aortic route thromboembolism leading ST segment elevation Myocardial Infarction (STEMI). The patient was referred to the Hub Hospital to undergo urgent coronarography. The examination excluded atherosclerotic coronary arteries disease but an unusual persistence of contrast dye was found at the level of non-coronary sinus. The trans-esophageal echocardiography showed a mobile pedunculated echogenic ma…

Malemedicine.medical_specialtybusiness.industryAcute Inferior Myocardial InfarctionThrombosisGeneral MedicineInferior Wall Myocardial InfarctionSinus of ValsalvaCoronary embolismmedicine.diseaseInternal medicinemedicineCardiologyHumansThrombusMyocardial Infarction with Non Obstructive Coronary Artery (MINOCA) Aortic routeThrombectomy Coronary EmbolismCardiology and Cardiovascular MedicinebusinessCoronary sinusAgedCoronary artery disease
researchProduct

Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study

2017

Essentials Isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer. No study has specifically evaluated the long-term clinical course of cancer-associated IDDVT. Patients with cancer-associated IDDVT are at very high risk of symptomatic recurrence and death. We observed low rates of major bleeding during anticoagulation. SummaryBackground Although isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer, no study has specifically evaluated the long-term clinical course of IDDVT in this setting. Aim To provide data on the rate of recurrent venous thromboembolism (VTE), major bleeding events and death in IDDVT patients with active cancer. Pat…

Malemedicine.medical_specialtydistal deep vein thrombosis; mortality; neoplasm; observational study; venous thromboembolism; HematologyTime FactorsDeep veinHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsNeoplasmsInternal medicinemedicineHumans030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesVenous ThrombosisHematologybusiness.industryIncidenceClinical courseAnticoagulantsCancerdistal deep vein thrombosiVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasemortalityThrombosisSurgeryTreatment Outcomemedicine.anatomical_structureItalyobservational studyFemaledistal deep vein thrombosisPulmonary EmbolismbusinessVenous thromboembolismneoplasmDistal deep vein thrombosis; Mortality; Neoplasm; Observational study; Venous thromboembolism; Hematologymedicine.drugCohort studyJournal of Thrombosis and Haemostasis
researchProduct

Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin).

1991

Despite the improvements in the development of dialyzer membranes with greater hemocompatibility, an activation of the coagulation system occurs when blood comes into contact with exogenous surfaces. The large number of heparin dosage regimens demonstrate the difficulty to adapt general therapeutic guidelines. Low molecular weight heparin (Fragmin®) was administered as a single bolus dose for anticoagulation during 58 acute dialyses. Anti-Xa-activity, the plasma levels of the lysosomal elastase of the polymorphnuclear granulocytes (“PMN-elastase”) and of the thrombin-antithrombin III-complex (TAT) were measured at hourly intervals. Therapeutic anti-Xa-levels did not show evidence of suffici…

Malemedicine.medical_specialtymedicine.drug_classAntithrombin IIILow molecular weight heparinPharmacologyCritical Care and Intensive Care MedicineRenal DialysismedicineHumansPancreatic elastaseAgedbiologyPancreatic Elastasebusiness.industryElastaseAnticoagulantThrombosisHeparinAcute Kidney InjuryHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryCoagulationNeutrophil elastasebiology.proteinFemalebusinessLeukocyte Elastasemedicine.drugPeptide HydrolasesIntensive care medicine
researchProduct

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

2010

SummaryThis trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embol…

Malemedicine.medical_specialtymedicine.drug_classArthroplasty Replacement HipInjections SubcutaneousAdministration OralLow molecular weight heparinHemorrhage030226 pharmacology & pharmacyAntithrombinsDabigatranlaw.invention03 medical and health sciencesPostoperative Complicationsoral thromboprophylaxis dabigatran flebography0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineEnoxaparinAgedVenous Thrombosisbusiness.industryAnticoagulantAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseSurvival AnalysisDabigatranSurgeryPulmonary embolismVenous thrombosisDirect thrombin inhibitorAnesthesiabeta-AlanineBenzimidazolesFemalebusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Anticoagulation prescription in atrial fibrillation.

2011

We seek to assess the factors associated with the anticoagulation prescription in a cohort of patients with atrial fibrillation (AF) collected from out-patient clinics.A total of 1524 patients with a history of AF were collected from out-patients clinics. CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were calculated in every patient. Variables associated with anticoagulant treatment prescription were analyzed in univariant and multivariant models.Most patients received either anticoagulant (62%) or antiplatelet treatment (37%). Anticoagulation rates increased among higher CHADS(2) and CHA(2)DS(2)-VASc score values. A logistic regression model was performed to assess the variables associate…

Malemedicine.medical_specialtymedicine.drug_classHemorrhageLogistic regressionAmbulatory Care FacilitiesRisk FactorsInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Medical prescriptionPractice Patterns Physicians'AgedPharmacologyAged 80 and overbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationThrombosisGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLogistic ModelsAnticoagulant therapyConcomitantCohortMultivariate AnalysisCardiologyFemalebusinessPlatelet Aggregation InhibitorsExpert opinion on pharmacotherapy
researchProduct

Factors responsible for interindividual differences in the dose requirement of phenprocoumon

1987

The total and unbound plasma concentrations of phenprocoumon and the prothrombin complex activity were determined in 51 patients on phenprocoumon. A 7-fold difference in the dosing rate (10-70 micrograms/kg/day) was required to maintain the prothrombin complex activity at 11-30% of normal. The variation in dosing requirement was mainly due to interindividual differences in the intrinsic clearance of phenprocoumon and only to a minor degree to differences in sensitivity to it. On average patients with myocardial infarction required only 2/3 of the daily dose of phenprocoumon of post cardiac surgery patients and patients with thrombosis and emboli. That difference appeared to be due to higher…

Malemedicine.medical_specialtymedicine.drug_classIndividualityPhenprocoumonPharmacokineticsInternal medicinemedicineHumansPharmacology (medical)Myocardial infarctionDosingPharmacologyChemistryCoronary ThrombosisAnticoagulant4-HydroxycoumarinsGeneral MedicineMiddle Agedmedicine.diseaseThrombosisCardiac surgeryEndocrinologyPhenprocoumonProthrombin TimeCardiologyFemaleProtein Bindingmedicine.drugSurgical patientsEuropean Journal of Clinical Pharmacology
researchProduct

Embolic stroke, sinus rhythm and left atrial mechanical function

2004

A 64-year-old man manifested a stroke two years after restoration of sinus rhythm through a radiofrequency catheter ablation. Transesophageal echo- cardiography demonstrated the presence of a thrombus in the left atrial appendage. Left atrial volumes and different parameters of atrial emptying showed that, de- spite the persistence of the sinus rhythm, atrial mechanical function was severely impaired. After atrial ablation procedures echocardiography can be useful to stratify pa- tients according to their risk of developing embolic events and hence be of help in deciding whether or not discontinuation of anticoagulant therapy is the appropri- ate choice.

Malemedicine.medical_specialtymedicine.medical_treatmentElectric CountershockAtrial AppendageCatheter ablationInternal medicineAtrial FibrillationmedicineHumansAtrial AppendageRadiology Nuclear Medicine and imagingSinus rhythmcardiovascular diseasesThrombusAtrium (heart)business.industryInfarction Middle Cerebral ArteryThrombosisAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseThrombosisEchocardiography DopplerStrokemedicine.anatomical_structureIntracranial EmbolismAnesthesiaCatheter Ablationcardiovascular systemCardiologyAtrial Function LeftAtrial AblationTomography X-Ray ComputedCardiology and Cardiovascular MedicinebusinessBlood Flow VelocityEchocardiography TransesophagealEuropean Journal of Echocardiography
researchProduct

Acute coronary artery closure following intracoronary ultrasound examination

1995

Two patients undergoing intracoronary ultrasound examination were complicated by acute coronary artery closure. One of the complications was thought to be caused by intimal dissection and thrombus formation and the other was thought to be caused by intimal dissection and subsequent embolization. The complications were successfully managed conservatively in both cases. © 1995 Wiley-Liss, Inc.

Malemedicine.medical_specialtymedicine.medical_treatmentEmbolismCoronary DiseaseConstriction PathologicCoronary AngiographymedicineHumansEmbolizationThrombusUltrasonography InterventionalIntimal Dissectionbusiness.industryCoronary ThrombosisfungiMiddle AgedCoronary artery closuremedicine.diseaseCoronary VesselsThrombosisSurgeryAcute DiseaseCirculatory systemIntracoronary ultrasoundRadiologyCardiology and Cardiovascular MedicineComplicationbusinessCatheterization and Cardiovascular Diagnosis
researchProduct

The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein …

2013

The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched co…

Malemedicine.medical_specialtymedicine.medical_treatmentGastroenterologychemistry.chemical_compoundPostoperative ComplicationsGene FrequencyRisk FactorsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1Factor V LeidenmedicineOdds RatioHumansGenetic Predisposition to Disease4G/5G genotype PAI-1 thrombotic lesionsPromoter Regions GeneticAllelesAgedVenous ThrombosisPolymorphism Geneticbusiness.industryHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseNadroparin calciumThrombosisSurgerychemistryPlasminogen activator inhibitor-1Case-Control StudiesFemalebusinessPlasminogen activatorAbdominal surgerymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct